4 ms·
Collectively, we need to get over the idea of all-or-nothing solutions to Coronavirus. We're not going to wake up one day with a "cure" for COVID-19. No one i
by PragmaticPulp 7y ago
Collectively, we need to get over the idea of all-or-nothing solutions to Coronavirus.
We're not going to wake up one day with a "cure" for COVID-19. No one in the medical field actually expects Hydroxychloroquine to produce miraculous recoveries at this point. The idea is that any treatment that slows the progress of the infection will also buy the patient's immune system more time to fight the infection. If we can push the peak symptoms back even 1-2 days relative to untreated individuals, that gives the immune system that much extra time to mount an effective defense against the virus.
When we finally confirm which treatments, if any, are useful for slowing the progress of the infections, we can combine them with earlier testing and identification to help reduce the number of patients who require hospitalization. It won't look like a cure, but it will be making improvements in treatment outcomes and reducing the burden on hospitals.
At this scale, a small modification of disease severity can still be useful for minimizing the burden on hospitals, even if it doesn't fit the narrative of a miracle cure.
- gus_massa 7y ago> The idea is that any treatment that slows the progress of the infection will also buy the patient's immune system more time to fight the infection. Is there any serious trial that shows that Hydroxychloroquine has any effect at all?
- Mountain_Skies 7y agoDouble blind peer reviewed trials are a good goal but in the middle of a crisis you can't let a desire for perfection get in the way of the good. There is enough imperfect evidence that this treatment stack (that is, several drugs used in combination with hydroxychloroquine) has benefits that it should be considered a potential part of a solution. Waiting a couple of years for perfect studies to be carefully conducted is waiting until the crisis is over and the treatment moot. What is well known are the side effects of this drug, their likelyhood, and how to ameliorate them.
- gus_massa 7y ago> There is enough imperfect evidence that this treatment stack [...] has benefits that it should be considered a potential part of a solution. Is there any evidence? Do you have a link to the best evidence so far? Did someone tried a similar treatment and get the same result? It is not necessary to have a perfect study, because there too little time. But how hard is to make a study with a randomized control group? You are not sure if this drug is better or worse, so giving only the standard treatment perhaps is better. I guess a double blind experiment is more difficult for logistic reasons, but if the patients have respirators and are sedated, it is almost a single blind experiment. And if the results are the number of death or an analysis in a lab by a machine (instead of self reports), they can be less influenceable.
- brutt 7y agoSee there: https://www.mediterranee-infection.com/covid-19/ https://www.mediterranee-infection.com/covid-19/
- pbreit 7y agoYes, there is quite a bit of evidence. Proven against SARS in vitro: https://www.ncbi.nlm.nih.gov/pubmed/15351731 https://www.ncbi.nlm.nih.gov/pubmed/15351731 And much evidence for efficacy against COVID-19 in humans: https://twitter.com/__ice9/status/1246549028382408706 https://twitter.com/__ice9/status/1246549028382408706
- travisporter 7y agohttps://www.medrxiv.org/content/10.1101/2020.03.22.20040758v2 https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v... Note that it is not peer reviewed
- gus_massa 7y agoThanks for the link, it looks good. This part is strange: > Normalization and mitigation criteria included the following: a. Body temperature ≤ 36.6 °C on the surface, ≤ 37.2 °C under the armpit and mouth or ≤ 37.8 °C in the rectum and tympanic membrane; Is this a standard criteria? Why didn't they agree to use the same measurement method in all the study? The part about counting coughs is not convincing for me, it looks too difficult to measure accurately. I prefer to ignore it. But this part looks really interesting: > Notably, a total of 4 of the 62 patients progressed to severe illness, all of which occurred in the control group not receiving HCQ treatment. For adverse effects, it should be noted that there were two patients with mild adverse reactions in the HCQ treatment group, one patient developed a rash, and one patient experienced a headache, none severe side effects appeared among them.
- pbreit 7y agoThere are several. Plus it does have proven effect against SARS in vitro. And this French treatment center seems to be getting good results. https://www.mediterranee-infection.com/covid-19/ https://www.mediterranee-infection.com/covid-19/